Vaxxas key facts
as of Oct 2026- Developer of a needle-free vaccine delivery system designed to enhance the performance of existing and next-generation vaccines.
- Vaxxas is valued at approximately $235.6M as of Oct 2026 (last reported valuation).
- It has raised $154.3M; the latest was Later Stage VC ($58.0M) in Aug 2025.
- Notable investors include Gates Foundation, QIC, Wellcome Trust, Brandon Capital, SPRIM Global Investments — 22 tracked in total.
- Status: Privately Held (backing).
Vaxxas's last reported valuation, Aug 2025. Nothing priced has surfaced since.
- ·The complete investor list: 22 names
- ·Watch Vaxxas: the Monday email on marks, rounds and moves
Vaxxas funding rounds
No funding rounds for Vaxxas are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Vaxxas
22+Vaxxas valuation
Vaxxas's last reported valuation was $236 million in Aug 2025. No priced round, secondary trade or fund mark has surfaced since.
Vaxxas investors
22 investors are on record for Vaxxas, including Gates Foundation, QIC, Wellcome Trust and Brandon Capital.
About Vaxxas
Developer of a needle-free vaccine delivery system designed to enhance the performance of existing and next-generation vaccines. The company's system consists of an array of vaccine-coated microprojections that perforate the outer layers of the skin when applied with an applicator device, enabling medical practitioners to directly deposit vaccine amongst a dense population of immune cells in the skin.
- Sector
- Healthcare
- HQ
- Hamilton, Australia
- Founded
- 2011
- Employees
- 129
- Website
- vaxxas.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.